Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 10, 2012

Progesterone Bullies MicroRNA in Breast Cancer

  • A mechanism by which progesterone promotes estrogen receptor (ER)- and progesterone receptor (PR)-positive breast cancers to become more stem-like, aggressive and resistant to standard endocrine and chemotherapies is described by researchers at the University of Colorado, Denver. Their results indicate that one particular microRNA, miR-29, may represent a druggable target for helping to prevent the cancer from converting into a treatment-resistant phenotype.

    The expansion of hormone receptor-positive breast cancer cells is associated with loss of ER and PR expression, and upregulation of the tumor-initiating marker CD44 and progenitor marker cytokeratin 5 (CK5). However, the mechanisms underlying this hormone-stimulated reprogramming have remained mainly elusive, report Diana Ciettelly, Ph.D., Jennifer Richer, Ph.D., and colleagues.

    Looking more closely at the role of miRNAs in progesterone-mediated dedifferentiation and expansion of tumor cells, the researchers found that the hormone acts to downregulate miR-29 family members, particularly in the CD44+ cell population. Their studies showed that downregulation of miR-29 enhanced the expansion of CK5+ and CD44+ cells in response to progestins, resulting in increased stem-like properties both in vitro and in vivo.

    “The reason we were looking into the possible role of microRNAs in the dedifferentiation of breast cancer cells into this aggressive, chemo-resistant phenotype is that microRNAs tend to be good, druggable targets,” Dr. Cittelly states. “Because one microRNA may regulate many genes involved in a cancerous signaling pathway, we hoped to find one target with many beneficial effects.”

    Having implicated miR-29 in this process, the team carried out additional experiments suggesting that miR-29 directly targets the transcription factor Krüppel-like factor 4 (KLF4), which is involved in reprogramming differentiated cells back into pluripotent stem cells and the maintenance of breast cancer stem cells.

    The researchers report their findings in Oncogene, in a paper titled “Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.” Dr. Cittelly hopes the new insights will help lead to new anticancer treatment approaches. “We can manipulate this miR-29 in cell lines, and we hope technology isn’t too far in the future that will allow us to deliver miR-29 in human cancers as well.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »